FY March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Business Performance

For the third quarter of the fiscal year ending March 2026, consolidated financial results showed net sales of 98,857 million yen (0.5% year-over-year decrease), operating income of 16,400 million yen (5.7% year-over-year decrease), ordinary income of 16,762 million yen (6.8% year-over-year decrease), and net income attributable to owners of the parent of 11,726 million yen (5.2% year-over-year decrease). By segment, net sales decreased in the Clinical Examination Equipment and Patient Monitoring Equipment segments, while the Therapeutic Equipment and Consumables segments recorded increases. Despite addressing market conditions influenced by Medical DX promotion and regional medical care initiatives, a declining trend was observed on the profit side.

Financial Position and Dividend Status

Total assets decreased by 5,353 million yen from the end of the previous consolidated fiscal year to 215,968 million yen, liabilities decreased by 5,234 million yen to 34,434 million yen, and net assets decreased by 118 million yen to 181,533 million yen. The amount of treasury stock has increased due to share buybacks. The annual dividend forecast for the fiscal year ending March 2026 is 180 yen (90 yen interim and 90 yen year-end), maintaining the same level as the previous fiscal year. There is no revision to the earnings forecast, and while remaining cautious about the uncertain economic environment, results are expected to proceed roughly as forecasted.